INDIA- American multinational pharmaceutical and biotechnology company, Pfizer has said that its managing director Sridhar, has left the organization.

The corporation has stated in a regulatory statement that Sridhar has indicated his desire to retire early and has submitted his resignation.

Sridhar has worked for Pfizer for more than ten years in various capacities, including Chief Financial Officer, Commercial Lead, Country Manager and Managing Director.

He has served as the Managing Director for Pfizer for the last 6 years. During this time, he led several strategic initiatives that have significantly increased the company’s market share in the nation.

With the release of multiple ground-breaking medications in the fields of oncology, rare diseases, vaccines, and anti-infectives, he has presided over the growth of Pfizer’s creative business in the nation.

He also successfully oversaw the merger of Wyeth Limited and Pfizer Limited in India, which allowed the two publicly traded companies to successfully combine their product and talent portfolios to strengthen their market presence.

Mr. Sridhar also serves as the President of the Organization of Pharmaceuticals Producers of India (OPPI).

The company stated that Sridhar significantly aided the expansion of the business’s portfolio, presence throughout India, and reach to patients who benefited from access to Pfizer treatments

For the fields of immunology, cancer, cardiology, endocrinology, and neurology, Pfizer develops and produces pharmaceuticals and vaccines.

Each of the company’s top-selling medicines or goods brings in more than $1 billion in annual sales.

52% of the company’s revenues came from the United States in 2020, compared to 6% from China and 6% from Japan, and 36% from other nations.

In response to the COVID-19 pandemic, Pfizer created and released a number of medications, including Paxlovid and the Pfizer-BioNTech COVID-19 vaccine.

The company joined the COVID-19 Therapeutics Accelerator funding vehicle in March 2020 to hasten the creation of COVID-19 therapies.

As of early May 2021, Pfizer and BioNTech had manufactured at least 430 million vaccine doses, which have been distributed to 91 countries and territories.

“Sridhar made a significant contribution to the growth of the company’s portfolio, presence across India and reach to patients who have benefited from access to Pfizer therapies,” the company said.

The company stated that Sridhar significantly aided the expansion of the business’s portfolio, presence throughout India and reach to patients who benefited from access to Pfizer treatments.

Mr. Sridhar will stay in his current role until the company has identified, chosen, and transitioned to the new leadership.

Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE